FindTrial
Sign In

Clinical and metabolic effects of rosiglitazone plus metformin and metformin only or rosiglitazone only in obese women with polycystic ovary syndrome and metabolic disorders: a randomized controlled trial

Clinical and metabolic effects of rosiglitazone plus metformin and metformin only or rosiglitazone only in obese women with polycystic ovary syndrome and metabolic disorders: a randomized controlled trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13003642
Enrollment
Unknown
Registered
2013-08-21
Start date
2013-10-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic ovary syndrome

Interventions

A:metformin (500mg, tid, 6months)
B:Rosiglitazone (4mg,qd,6months)
C:Rosiglitazone (4mg,qd,6months) and metformin (500mg, tid, 6months)

Sponsors

West China Second University Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
15 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Women diagnosed of PCOS; 2. BMI>=25 with fasting insulin>=20uu/ml or HOMA-IR>2.77.

Exclusion criteria

Exclusion criteria: 1. Women who are pregnant; 2. Women who have specified coexisting disease affecting the glycometabolism and lipid metabolism; 3. Women who receive hormonal therapy in the last three months; 4. Heavy smokers(>10 cigarettes/day); 5. BMI>35 kg/m2.

Design outcomes

Primary

MeasureTime frame
HOMA-IR;blood lipids;—

Secondary

MeasureTime frame
fat index;hyperandrogenic clinical manifestation;sex hormone;blood pressure;—

Countries

China

Contacts

Public ContactWei HUANG

West China Second University Hospital

1343174200@qq.com+86 28 85501346

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 1, 2026